Stichwortverzeichnis

3-HMG Co A-Reduktase ......................................... 18, 38 Arzneimitte1zulassung .................................................. 187 3-HMG-CoA-Hemmer ............................................ 18, 38 Mutual Recognition ............................................... 194 5-Iod-2-desoxyuridin .................................................... 30 Zentrales Verfahren ............................................... 187

Aspergillus .............................................................. 15, 18

A Asperlicin ...................................................................... 39 Aufschlussmethoden ..................................................... 98

A. rhizogenes ............................................................... 169 A. tumefaciens ....................................................... , ..... 169 Abgabebehiiltnis .......................................................... 103 Acarbose ....................................................................... 38

Augentropfen .............................................................. 197 Autoimmunerkrankungen ........................................... 216 Automatisierung ........................................................... 77 Avonex® ..................................................................... 220

Actinomycin .................................................................. 27 Acy1oxymeihy1-Derivate ............................................. 118 Adenoassozierten V ire ................................................ 148

B Adjuvantien ................................................................. 132 Baby Hamster Kidney ................................................... 20

Antikorperbildung .................................................. 132 Bacillus ......................................................................... 15 Aerosol ........................................................................ 118 Bacillus subti/is ............................................................. 28 AERx®-System ........................................................... 122 BAC-Plasmid .............................................................. 153 Aflatoxin ....................................................................... 24 Balhimycin .................................................................... 39 Agarsuspensionstest .................................................... 198 Basalzellkarzinom ....................................................... 216 Agrobacterium ............................................................ 169

T-DNA ................................................................... 169 Basiliximab ................................................................. 230 Benzonase® ................................................................... 91

Ti-P1asmide ............................................................ 169 Betaferon ® .................................................................. 219 Airlift Bioreaktor ........................................................... 85 Knlberserum ............................................................ 80 Airlift-Prinzip ................................................................ 79 Betaseron® .................................................................. 219 Ajmalicin .................................................................... 171 Albumax® ..................................................................... 80

Betriebshygiene .......................................................... 198 Betriebsstorungen ......................................................... 87

Algorithmus BHK-21 C13 ................................................................. 21 BLAST .................................................................. 180 Biobalistik ................................................................... 146 FASTA .................................................................. 180 Bioinformatik .......................................................... 1, 175 Suffix ..................................................................... 180

Alkaloide ~:~{~~~~~::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: :~~ Vinca-Alkaloide ....................................................... 34 Biolistik ...................................................................... 170

Allergien ..................................................................... 115 Bioprozessanalytik Aluminiumhydroxid .................................................... 133 Gasdruck .................................................................. 87 Alveolen ...................................................................... 119 Gasdurchsatz ........................................................... 87 Alzet® .......................................................................... 123 Ionenkonzentration ........................ , ......................... 87 Amplifikation ................................................................ 55 pH-Wert ................................................................... 87 AnalytiCon Drug Discovery .......................................... 75 Sauerstoffgehalt ....................................................... 87 Antibiotika .................................................................... 18 Schaumstand ............................................................ 87 Antikorper Temperatur .............................................................. 87

Antidot ................................................................... 227 TrUbung ................................................................... 87 Anwendung ............................................................ 226 Bioprozesskontrolle ...................................................... 87 chimllrer ................................................................. 230 Offline-Messung ...................................................... 87 humanisierter ......................................................... 230 Online-Messung ...................................................... 87 Hybridomverfahren ................................................ 226 Biostat-Verfahren ......................................................... 82 Markierung ............................................................ 227 Biotechnologie ................................................................ 3 monoklonaler ......................................................... 226 Geschichte ................................................................. 5 polyklonal .............................................................. 226 BLAST-Algorithmus .................................................. 180 radioaktiver ............................................................ 227 Blastozyste .................................................................. 160

Antikorperbildung ....................................................... 115 Blotting-Verfahren Antisense Therapie ...................................................... 143 Dot-Blotting ............................................................. 59 Antisense-Oligonukleotide .......................................... 143 E1ektroblotting ......................................................... 59 Antitrypsin .................................................................... 16 Kapillarblotting ....................................................... 59 Apothekenumsntze .......................................................... 9 Northern .................................................................. 59 Arbeitszellbank ............................................................. 47 Southern .................................................................. 59 Arcitumomab .............................................................. 228 Western .................................................................... 59 Artifizielle Organe ...................................................... 165 Bodenzahl................................................................... 109 Arzneibuch-Monographie ........................................... 195 BSE ............................................................................. 200 Arzneimittel BfArM ................................................................... 200

Liste A ................................................................... 187 Nnhrmedien ........................................................... 200 Liste B ................................................................... 188 RUckrufe ................................................................ 20 I

Arzneimittelgesetz ...................................................... 151 Bulkware ..................................................................... 107 ArzneimittelrUckstande ............................................... 164

250 Stichwortverzeichnis

c Distribution ................................................................. 112 DNA

CaianolidA ................................................................... 36 Copy-DNA .............................................................. 25 Calicheamicin ............................................................... 38 Gefrier1rocknung ..................................................... 48 .Calophyllum lanigerum ................................................. 36 Hybridisierung ......................................................... 55 Capping ......................................................................... 58 Interkalation ............................................................. 27 Capture-Schritt ............................................................ 136 Isolierung ................................................................. 25 Carboxypeptidase A ...................................................... 99 mitochondriale ......................................................... 12 Carboy-Systeme .......................................................... 171 Nukleotide ............................................................... 23 CEA-Scan'" ......................................................... 228, 229 pharmazeutische Zwecke ......................................... 25 Celera Genomics ......................................................... 153 PhenollChloroform-Extraktion ................................ 25 CellCube'" .................................................................... 135 Plasmid .................................................................... 23 Chemostat-Verfahren .................................................... 82 Polymerase .............................................................. 25 Chemtech .................................................................... 214 Sequenzierung ......................................................... 53 Chinese Hamster Ovar .................................................. 20 Syntheseautomat ...................................................... 58 Chitosan ...................................................................... 117 Z-Form .................................................................... 24 Chloramphenicol ........................................................... 30 Chloroform .................................................................... 92

DNA-Chip .............................................................. 56, 61 DNA-Microarray-Technik ............................................ 61

CHO-dhfr-Linie ............................................................ 21 DNA-Sequenz ............................................................. 139 Cholera-lmpfstoff. ............................................... 126, 127 Choriongonadotropin .................................................. 221 CHO-Zellen ................................................................... 20

DNA-SOnden .............................................................. 198 DNA-Syntheseautomat ................................................. 58 DNA-Vakzine ............................................................. 130

Chromatographie ........................................................... 97 Docetaxel ...................................................................... 35 Plasmaproteine ......................................................... 97 Doknmentation ........................................................... 176

Chromosomen ............................................................... II Domllne ....................................................................... 129 Ciclosporin A ................................................................ 38 ClP-Reinigung .............................................................. 96

Doppelblindstudien ..................................................... 204 Downstream-Prozess .................................................... 79

Circulardichroismus .................................................... 109 Drug Delivery ............................................................. 116 CJD ............................................................................. 201 Drug Targeting ............................................................ 116 Cleaning in Place .......................................................... 96 Durchflusszytometrie .................................................... 67 Computer .................................................................... 175 pharmazeutische Anwendung .................................. 68 Co-Rapporteur ............................................................. 188 Dilsenseparator ............................................................. 95 Co-Solventien ............................................................. 105 Creutzfeldt-Jakob-Erkrankung .................................... 201 Cross-Flow-Filtration .................................................... 96

E Croton lechleri .............................................................. 36 Edman-Abbau ............................................................... 64 CVMP ......................................................................... 187 Elektroblotting .............................................................. 60 Cyanbromidspaltung ................................................... 214 Ablauf.. .................................................................... 60 Cyanogenbromid ........................................................... 17 Elektrofusion .............................................................. 147 Cycle-Pressure-Reaktor ................................................. 85 Cyclothialidin ................................................................ 39

EI~~op?ration .................................................... 147, 170 ElImmatlOn ................................................................. 113

Cytokinine ..................................................................... 51 hepatisch ................................................................ 114 Cytomegalovirus ........................................................... 90 renale ..................................................................... 114

ELISA

D Herzinfarkt .............................................................. 67 Schwangerschaft ...................................................... 67

Daclizumab ................................................................. 230 E-Mail ......................................................................... 176 Data-Mining ................................................................ 175 Embryonenschutzgesetz ......................................... 41, 140 Datensicherheit ........................................................... 178 EMEA ......................................................................... 187 Deamidierung .............................................................. l05 Endonukleasen .............................................................. 31 Delphi-Studie .................................................................. 4 Endophyten ................................................................... 35 Denaturierung ............................................................. 105 Endoplasmatisches Retiknlum ...................................... 12 Dendrimere ................................................................. 146 Endotoxine .............................................................. 16,89 Desinfektion ................................................................ 198 Endozytose................ .......................................... ........ 119 Detergentien .................................................................. 92 Endreinigung ................................................................ 93 Dextran .......................................................................... 98 Enediyn-Derivate .......................................................... 38 Diaguostik Engerix B"' .................................................................. 138

Cholesterin-Transfer-Protein ................................... 62 Enterale Applikation ................................................... 116 ELISA ...................................................................... 67 Entwicklungskosten ........................................................ 8 prllnatai .................................................................... 62 Enzymimmunoassays .................................................... 67 Transplantation ........................................................ 62 Epibatidin ...................................................................... 35

Dichtedifferenzzentrifugation ....................................... 94 Epitop ......................................................................... 129 Didesoxynukleotide ...................................................... 54 Epstein-Barr-Virus ........................................................ 90 Dielektrophorese ......................................................... 147 Dikotylen .................................................................... 170

Erfindung .................................................................... 183 Erypo'" ........................................................................ 215

Dioleoylphosphatidylethanolamine ............................. 146 Erythropoetin .............................................................. 214 Diosgenin ................................................................ 5, 171 Erythropoetin alpha .................................................... 215

Stichwortverzeichnis 251

Erythropoetin beta ....................................................... 215 In vivo ................................................................... 142 Esperamicin ................................................................... 38 Inhibition............................................ ........... ........ 140 Ethikkomrnission ........................................................ 166 Sicherheit. .............................................................. 150 Eukaryota ...................................................................... 11 Substitution ............................................................ 140 Europaische Arbeitsgemeinschaft fiir Phanna Zulassung .............................................................. 151

Biotechnologie ........................................................... 3 Gewebetargeting ......................................................... 112 European Medicines Evaluation Agency .................... 187 Ginseng ....................................................................... 171 Ex vivo Therapie ......................................................... 142 Gliablastom ................................................................. 144 Expressed sequence tag ............................................... 154 Glucagon ..................................................................... 104 Expressionsvektor KMAC-43 ..................................... 218 Glycokalyx .................................................................... 11

Glykoproteine ............................................................. 101

F Glykosilierung .............................................................. 16 Gonal F® ..................................................................... 22 I

FASTA-AIgorithmus .................................................. 180 Good Laboratory Practise ............................................. 4 I Feinreinigung ................................................................ 93 Good Manufacturing Practise ....................................... 4 I Fermentech .................................................................. 214 Gradienten-Ultrazentrifugation ................................... 136 Fertigarzneirnitlel ........................................................ 187 GRAS ........................................................................... 15 Fertigspritze ................................................................ 137 Grippeschutzmitlel. ..................................................... 133 Festphasenextraktion ..................................................... 74 Fibroblasten ................................................................... 21 Filterkuchen .................................................................. 94

H Filtration ........................................................................ 96 Haarzell-Leukiimie ..................................................... 2 I 6 First-Pass-Effekt .......................................................... 117 Hairy Roots ................................................................. 170 Flag ............................................................................... 99 Hiimocyanin ................................................................ 129 Flotation ........................................................................ 87 Fluad® ......................................................................... 133

Hansenula polymorpha ............................................ ..... 18 Hapten ........................................................................... 67

FluMist®, ..................................................................... 133 Harvard-Maus ............................................................. 186 FIOssig-Stickstoff-Methode ........................................... 48 Havrix® ....................................................................... 138 Follikel stimulierendes Hormon .................................. 221 Helicobacter pylori ..................................................... 173 Follitropin alpha .......................................................... 221 Helios® ........................................................................ 147 Follitropin beta ...................................................... 81,222 Hepatitis B-Impfstoff .................................................. 126 Food and Drug Administration ..................................... 41 Herceptin ® .................................................................. 229 Foot-and-mouth-disease-virus ..................................... 129 Heterokaryon .............................................................. 168 Fractogel ....................................................................... 98 High-Throughput-Screening ................................... 55,73 Fremd-DNA ............................................................ 11,91 Hirudin ........................................................................ 225 FSH ............................................................................. 221 Hirudo medicinalis ..................................................... 225

Mutein .................................................................... 222 Hochdosistherapie ....................................................... 14 I Functional Genomics .................................................... 77 Hochdruckhomogenisation ........................................... 98

HochdruckfiOssigkeitschromatographie ...................... 109

G Hochleistungsrechner .................................................. 176 Hochleistungsstiimme ..................................................... 6

Gallensalze .................................................................. 118 Homogenisieren ............................................................ 83 Ganciclovir .................................................................. 141 Hosch-Filter .................................................................. 42 Gefriertrocknung ........................................................... 47 Filterleistung ............................................................ 43

Mist desiccans .......................................................... 48 HPLC-MS ..................................................................... 63 Zuckeralkohole ........................................................ 47 HUGO ......................................................................... 153

Gefriertrocknungsprozess ........................................... 104 HOhnerembryonen ...................................................... 134 Gelelektrophorese ......................................................... 66

Coomassie Blau ....................................................... 66 HOhnerfibroblasten ..................................................... 134 Humalog® ................................................................... 209

Ethidiumbromid ....................................................... 66 Humangenom-Projekt. ................................................ 152 Natriumdodecylsulfat... ............................................ 66

GenH-B-Vax® ............................................................ 138 HUGO ................................................................... 152

Humaspect® ................................................................ 229 Gene-Gun .................................................................... 170 Humatrope® ................................................................ 224 Genetischer Fingerabdruck ........................................... 13 Hybridisierung Genitalwarzen ............................................................. 216 in-situ ....................................................................... 56 Genomforschung ............................................................. 1 Hybridomverfahren ..................................................... 226 Genomics .................................................................... 175 HybridzOchtung .......................................................... 167 Genotropin ® ................................................................ 224 Hydrogele ................................................................... I 17 Gen-Phanning ..................................................... 158, 163 Hypophyse .................................................................. 221 Gentaxis ...................................................................... 144 Gentechnikgesetz .................................................. 41, 195 Gentechnologie ............................................................... 3 I Gentherapie ................................................................. 139 Immunfluoreszenzverfahren ....................................... 227

Addition ................................................................. 140 Immunisierung ............................................................ 125 Antisense ............................................................... 142 lnununo-ELISA-Testverfahren ..................................... 90 Ex Vivo .................................................................. 142 Immunogenitiit... ......................................................... 115 Herstellung ............................................................. 151 Immunsuppression

252 Stichwortverzeichnis

Ciclosporin. .............................................................. 38 Impfstoffe

K Feinreinigung ......................................................... 136 Klilberserum .................................................................. 80 Herstellung ............................................................. 134 Kallusgewebe .............................................................. 168 Ultrafiltration ......................................................... 136 Kaninchen-Test ........................................................... 199 Vorreinigungprozess .............................................. 136 Keimbahntherapie ....................................................... 140

ImpfstofIProduktion ...................................................... 21 Klenow-Fragment ......................................................... 54

=::~I~~::::::::::::::::::::::::::::::::::::::::::::::::::::::::::~~~ Klinische PrOfverfahren Phase I-IV .............................................................. 203

Imukin4l> ....................................................................... 220 PrlIklinik ................................................................ 203 in vitro Fertilisierung .................................................. 158 Klonierung .................................................................. 157 in vivo Therapie .......................................................... 142 Kluyveromyces loctis .................................................... 18 Indimacis4l> ................................................................... 229 KMU ............................................................................... 8 lnferax4l> ....................................................................... 218 Knock-Out-Mliuse ...................................................... 162 Inflexal S4I> ................................................................... 138 Kllhler ......................................................................... 226 Informationsflut .......................................................... 175 Kombinatorische Biochemie ......................................... 72 lnformationsgesellschaft ............................................. 175 lnhale-System4l> ........................................................... III Injektion ...................................................................... 116 Inklusionskllrper ............................................................ 16 Inokulum ....................................................................... 48

Kombinatorischen Chemie ............................................ 69 Parallelsynthese ....................................................... 70 Prinzip ..................................................................... 70 TeileundMische ..................................................... 71

Kombinatorische Genetik ............................................. 72 Insektenzelle ................................................................. 52 69 Insertionsmutagenese .................................................. 148 Instabilitllt ................................................................... 103

Komplementsystem .................................................... 165 Konfektionierung .......................................................... 92

chemische .............................................................. 104 Konformationsverlust ................................................. 106 physikalische .......................................................... 105

Insulin ............................................................. 16, 79, 206 Konservierungsmittel .................................................. 196 Kontarninationen ..................................................... 80, 88

Aufreinigung .......................................................... 208 Bedarf .................................................................... 207

Prionen ................................................................... 80 KryopJ1lzipitation .......................................................... 92

Biosynthese ............................................................ 206 Cyanogenbromidspaltung ...................................... 208 Diabetes ................................................................. 206

Kryoprotektoren .......................................................... 137 Kultivierungsmethoden ................................................. 48

pflanzliche Zellen .................................................... 51 E. coli ..................................................................... 208 S!iugerzellen ............................................................ 49 Gentechnologie ................. , .................................... 208 InkIusionskllrper .................................................... 214 Klassische Gewinnung ........................................... 207

Kultur diskontinuierlich ...................................................... 82

Kulturpflanzen ............................................................ 167 Mutein .................................................................... 208 Produktion ............................................................. 214 Struktur .................................................................. 206

L Tierinsulin .............................................................. 207 Lachs-Calcitonin ......................................................... 117 Vollsynthese .......................................................... 207 Lachssperma ................................................................. 56

Insulin aspart ....................................................... 209, 210 Lactobacillen ................................................................ 15 Insulin giargin ..................................................... 209, 212 LADME-Modell ......................................................... III Insulin lispro ............................................................... 211 Interferon a-2b ............................................................ 219 t::~.~~.~~.~.:::::::::::::::::::::::::::::::::::::::::::::::::::::: ~~~ Interferon alfacon-I ..................................................... 218 L-Azaserin .................................................................... 30 Interferon P-I b ............................................................ 219 LC-MS ........................................................................ I07 Interferon y-l b ............................................................ 220 Leberpassage .............................................................. 117 Interferon-a ................................................................. 216 Interferon-a-2b ........................................................... 218

Lebertransplant Orthoclone4l> OKT3 ................................................ 230

Interferone ................................................................... 216 Lepirudin .................................................................... 225 Funktionen ............................................................. 216 LeukoScan4l> ................................................................ 228 Immunabwehr ........................................................ 216 Lidocain ...................................................................... 123 Immunzellen .......................................................... 216 Ligasen ......................................................................... 32

Interferon-a-2a ............................................................ 218 Limulus-Tests ............................................................. 199 IntronA4I> ..................................................................... 218 Lipopolysaccharide ................................................ 16, 199 IPV-Merieux® ............................................................. 138 Lipoproteine ................................................................ 101 IPV-Virelon4l> .............................................................. 138 Liposomen

kationische ............................................................. 145

J PartikelgrllBe ......................................................... 145 Zeta-Potenzial ........................................................ 145

Jejunum ....................................................................... 117 Jetilizer4l> ...................................................................... 118

Louis Pasteur .................................................................. 5 Lovastatin ............................................................... 38, 39 Luciferase ..................................................................... 76 Lunge .......................................................................... 118 Lungenfibroblasten ..................................................... 134

Stichwortverzeichnis 253

M Mabtherallll ................................................................... 229 MALDI-TOF ........................................................... 63,65 Markerpeptid ................................................................. 99 Massenspektroskopie .................................................. 107 Master Cell Bank ............................................ 47, 83, 134 Medi-Jecto~ ............................................................... 123 Membranbioreaktor ....................................................... 86 MencevaxAC~ ..................................................... 138

~:::=:.~::::::::::::::::::::::::::::::::::::::::::::::::::::::::::·i~: Methacryls!lurepolymere ............................................... 98 Microcarrier Bioreaktor ................................................ 86 Miglitol ......................................................................... 38 Mikrobiologische Verunreinigungen ............................. 89

=~~~~~~:::::::::::::::::::::::::::::::::::::::::::.~.~'. ~~~ Mikrotrliger

~~~;~.~~~~::::::::::::::::::::::::::::::::::::::::::::::::::·!n Milstein ....................................................................... 226

~~:~;:~::~:~.:::::::::::::::::::::::::::::::::::::::::::::::::::·ii~ Mist desiccans ............................................................... 48 Mitochondrien ............................................................... 12 MKS-Virus .................................................................. 129 MoAbI7-1A ........................................................ 128, 230 Molekulare Biotechnologie ............................................. I Monacolin K ................................................................. 39

E~:~~~~~:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::H ~::::;t:o~~~.:::::::::::::::::::::::::::::::::::::::::::::::::::::::: !!~

Gentherapie ............................................................ 154 Multiple Sklerose ........................................................ 216

E§§?i;:;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~.:!! E~E~~;~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~·:ii

N Nacktschnecke ............................................................ 129 N!lhrsalze ...................................................................... 51 Namalwa-Zelllinie ...................................................... 217 Nasenschleimhaut ....................................................... 118 Nassmahlung ................................................................. 98 Natriumdodecylsulfat .............................................. 66, 98 Naturstofiforschung ......................................................... 6 Neocarzinostatin ............................................................ 38 Neurofibromatosis

Gentherapie ............................................................ 155 Neutral-Protamin-Hagedom-Insulin ........................... 212 N-Formylmethionin ................................................. 17,28 Nicht-invasive Gabe .................................................... 116 Nitroanilin ................................................................... 200

=!~:~~~.~~.i.~.:::::::::::::::::::::::::::::::::::::::::::::::::::.~~~ Novo Rapidllll ............................................................... 209 Nukleasen ...................................................................... 91

Nukleus ....................................................................... 139 Nutrichip ....................................................................... 62

o Oberfl!lchenfiltration ..................................................... 96 OncoScin~ ................................................................. 229 Onkomaus ................................................................... 186 Opsine ......................................................................... 170 Oral-Virelon® ............................................................. 138 Orthoclone OKT3® ..................................................... 229 Oxytocin ..................................................................... 118

p

Paclitaxel .............................................. .5, 33, 35, 51, 167 Panorexllll .............................................................. 128, 229

MoAbI7-IA .......................................................... 230 Parenteralia .......................................................... 119, 197 Partikel

p~!=~~:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::i:: Pasteurisation ................................................................ 92 Patent .......................................................................... 183

Definition .............................................................. 183

~~~f:~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~:~~~~~~~~~~~~~~~~~~~ III Patentrecherchen ......................................................... 175 Pstenttypen

Anwendungs-......................................................... 184

~=~~:::::::::::::::::::::::::::::::::::::::::::::::::::::::::: ::: V erfahrenspatent ................................................... 184

Paul-Ehrlich-Institut ................................................... 228 PEG 400 ...................................................................... 106 Pegasysllll ..................................................................... 219

::~:~~:~:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::;:·18~~~ Penicillium ................................................................ 7, 15 Peptidasen ................................................................... III Peptidbibliotheken ........................................................ 72 Peptide-Mapping ......................................................... 109 Peptidimpfstoff .................................................... 128, 129 Perfusions-Loop ............................................................ 87 Pestalotiopsis microspora ............................................. 35 Pflanzenextrakte ........................................................... 74 Pharma-Biotechnologie .................................................. 3

Arbeitsfelder .............................................................. 4 Defmition .................................................................. 3 Marktpotenzial ........................................................... 4

Pharmainformatik ....................................................... 175 Pharmakodynamik ...................................................... III Pharmakogenomik ........................................................ 56 Pharmakokinetik ......................................................... III Phospholipid-Doppelschicht ......................................... II Phosphoramidit ............................................................. 58 Phytohormone ............................................................. 168 Picha pastoris ............................................................... 18

:::~:!=~~~.~.::::::::::::::::::::::::::::::::::::::::::::::::::.~~~ Plasmide ....................................................................... 23 Plasmodium ................................................................ 126 Platelia® ...................................................................... 203

254 Stichwortverzeichnis .

Pluripotenz .................................................................. 160 Resorcinomycin ............................................................ 39 Pluronic ....................................................................... 106 Restriktionsendonukleasen ........................................... 31 Pneumopur® ................................................................ 138 Restriktionsenzym .................................................. 6, 153 Polishing ....................................................................... 98 Retikuloendotheliales System ..................................... 115 Polyhistidin ................................................................... 99 Reverse Transkriptase ................................................... 36 Polylysinrest .................................................................. 99 Rheumatoide Arthritis ................................................. 216 Polymerasekettenreaktion ............................................. 56 Rhizopus ....................................................................... 15

Ablauf ...................................................................... 56 Rifampicin .................................................................... 27 Polystyrenkugel.. ........................................................... 81 Rindfleisch .................................................................. 200 posttranslationale Verlinderungen ................................. 16 PowdeJject® ................................................................. 123

RNA Isolierung ................................................................. 25

Pr!lklinik ........................................................... .' .......... 203 m-RNA .................................................................... 24 Precursor ............................................................... 33, 167 ribosomale ............................................................... 24 prenatales Genscreening .................................................. 7 transfer-RNA ........................................................... 24 Primliraufreinigung ....................................................... 92 Robert Koch .................................................................... 5 Primlirmetaholismus ...................................................... 33 Roboteranlagen ............................................................. 73 Primllrsequenz ............................................................. 101 Robotorverfahren .......................................................... 77 Primer ............................................................................ 54 Roferon-A ................................................................... 218 Prionen Rilhrenzentrifugen ........................................................ 94

Jmmunkapillarelektrophorese ................................ 202 Prionics® -Test ............................................................. 202

Rollerf\aschen ...................................................... 135, 171 Rilntgenspektroskopie ................................................. 108

6H4-Antikilrper ...................................................... 203 Proanthocyanidine ......................................................... 36

Rote Liste ........................................................................ 7 Rilteln-Vaccinol® ........................................................ 138

SP-303 ..................................................................... 36 RUckmutante ............................................................... 126 Prodrugs ...................................................................... 118 Prograt® ........................................................................ 38 Projektmanagement.. ................................................... 176 s Prokaryota ..................................................................... 11 Saatgutsystem ............................................................. 196 Proteasebehandlungen ................................................. 135 Saatvirussystem .......................................................... 134 Proteasen ..................................................................... 111 Saccharomyces ............................................................. 15 Proteinbindung ............................................................ 112 Sacharomyces cerevisiae .............................................. 17 Protein-Chips ................................................................ 62 Proteinsequenzdatenbank ............................................ 180 Proteinsequenzierung .................................................. 109 Proteo1yse .................................................................... 105 Proteomanalysen ........................................................... 62

. Proteomics ................................................................... 175 Prilfinuster ................................................................... 204 Pseudomonas aeruginosa .............................................. 37 Pulmonale App1ikation ................................................ 118 PulmSol® ..................................................................... 111 Pulsfeld-Gelchromatographie ...................................... 153 Puregon® ............................................................... 81, 222 Puromycin ................................................................... 118 Pyralomycin .................................................................. 39 Pyrogene ..................................................................... 199

Saizen ® ....................................................................... 224 Salmonellen ................................................................ 198 Sandimmun® ................................................................. 38 Sanger-Methode ............................................................ 55 Saponine ..................................................................... 171 Schlaufenreaktoren ..................................................... 171 Schrligagarkulturen ....................................................... 47 Schubfllterzenrifugen .................................................... 94 SchwangerschaftsverhUtung ....................................... 125 Seimatoantlerium tepuiense .......................................... 35 Sekundlirstoffe .............................................................. 33 Sephadex ....................................................................... 98 Sequence tag site ......................................................... 154 Sequenzierautomaten .................................................... 55 Sequenzierung

Q 2D-PA-Gelelektrophorese ....................................... 53 Cycle Sequencing .................................................... 55

Qualitlltssicherung ....................................................... 189 Quartiirstruktur ............................................................ 101 Querstromfiltration ........................................................ 97

Edman-Abbau .......................................................... 63 MALDI-TOP ........................................................... 63 Maxam-Gilbert ........................................................ 53 Sanger-Coulson ....................................................... 53

Shikonin .......................................................................... 5 R Siebkorbzentrifuge ........................................................ 94

Rabipur® ..................................................................... 138 RapidTrace® .................................................................. 75

Siebschneckenzentrifugen ............................................. 94 Simulect® .................................................................... 229 Simulect® .................................................................... 230

Rapporteur ................................................................... 188 Raum-Zeit-Ausbeute ..................................................... 81 Rebif!' ......................................................................... 220 Recormon® .................................................................. 215

Refludan ® ................................................................... 225 Reinrliume ..................................................................... 42

Kategorien ............................................................... 44 ReoPro® ...................................................................... 229 Resistenzgen ............................................................... 141

Single Cell Protein ........................................................ 92 Size exclusion ............................................................... 98 Solid Lipid Nanopartikel .............................................. 32 Somatische Gentherapie ............................................. 139 Somatropin .................................................................. 223 Somazellen .................................................................. 160 Sortenschutzgesetz ...................................................... 186 Southern Blot ................................................................ 59 SPE-Kartusche .............................................................. 75 Spleissungsprozess ....................................................... 27

Stichwortverzeichnis 255

Spurenelemente ............................................................. 81 Chloramphenicol ..................................................... 30 Squalenemulsion ......................................................... 133 Stamaril® ..................................................................... 138

Transmissible spongiform encephalopathy ................. 200 Trenntechniken ............................................................. 93

Stamrnzellbank .............................................................. 47 Trisomie 21 Stamrnzellen ................................................................ 160 Gentherapie ........................................................... 155 Standard Operation Procedures ..................................... 41 Triton X-100 ................................................................. 98 Start Ups ......................................................................... 8 Trypanosoma .............................................................. 126 Starterkultur .................................................................. 80 Trypsin .......................................................................... 99 Sterilfilter ...................................................................... 90 TSE ............................................................................. 200 Sterilitat Turnomekrosefaktoren .................................................. 16

Prufung auf ............................................................ 197 Tumor-Suppressorgen p53 ............................................ 56 Sterilwerkbilnke ............................................................ 44 Tumorvakzine ............................................................. 150

Produktschutz .......................................................... 44 Tween ......................................................................... 106 Zytostatika ............................................................... 44 Typhoral® ................................................................... 138

Steroidhormonen ............................................................. 5 Streptogramin ................................................................ 39 Streptomyces ................................................................. 15 u Streptomycin ................................................................. 18 Strobilurine ................................................................... 39 Subunit-Impfstoffe ...................................................... 127

Uberziige magensafiresistent ................................................. 117 saurestabil .............................................................. 117

Surfactant .................................................................... 119 SWISS-Prot. ................................................................ 180

Ultra High Throughput ................................................. 76 Upstream-Prozess ......................................................... 79 US-PTO ...................................................................... 185

T Tacrolimus .................................................................... 38 v Taxol ............................................................................. 35 Vakzine T axomyces andreanae ................................................... 35 essbare ................................................................... 172 Taxotere ........................................................................ 35 Taxus brevifolia ............................................................ 35

orale Applikation ................................................... 172 van der Waals Krtlfie .................................................. 10 I

T-DNA ........................................................................ 169 Tecnemab® .................................................................. 229 Tellerseparator .............................................................. 95

Varilrix® ..................................................................... 138 Vektoren .............................................................. 139.144

AAV ...................................................................... 148 Tenside .......................................................................... 16 Tetanol® ...................................................................... 138 Tetracycline ................................................................... 30

Adenoviren ............................................................ 148 biologisch .............................................................. 144 chemisch ................................................................ 144

Thebain ....................................................................... 171 Thrombozytopenie ...................................................... 225

physikalisch ........................................................... 144 Retroviren .............................................................. 147

Thymidinkinase ........................................................... 141 TicoVac® ..................................................................... 138 Tiefenfiltration .............................................................. 96

V erfahrenstechnik ........................................................... 2 Vero-Affenierenzellen ........................................... 21.134 Verteilungsstudien ...................................................... 112

Tierversuche .................................................................. 68 Vibrio cholerae ........................................................... 173 Tight junctions ............................................................ 118 Viciafaba .................................................................... 171 Ti-Plasmide ................................................................. 169 Vinblastin ..................................................................... 33 Tissue Plasminogen Activator

Herstellung ............................................................. 161 Vinca-Alkaloide ..................................................... 34. 167 V inconat ....................................................................... 35

Transduktion ....................................................... 144. 157 Viren Transfektion .................................................. 31. 144. 157 Transferrin ..................................................................... 79

phytopathogen ....................................................... 171 Virtuelle Bibliothek ...................................................... 73

Transgen ...................................................................... 157 Virustransfektion .......................................................... 50 Stabilitat.. ............................................................... 164 Voglibose ...................................................................... 38

Transgene Pflanzen ..................................................... 167 Transgene Tiere

Kuh ........................................................................ 163 w Maus ...................................................................... 162 Schaf ...................................................................... 161 Schwein ................................................................. 165

Transkription ................................................................. 27 Operon ..................................................................... 29 RNA ......................................................................... 27 Spleissungsprozess ................................................... 27

Translation .................................................................... 28

Wannenstapel.............................................................. 135 Warmeaustausch ........................................................... 83 Western-Blot. ................................................................ 60 Wirt-Vektor-System ................................................... 196 Wolfram-Partikel ........................................................ 170 Working Cell Bank ................................................. 47. 83 Wurzelhalsgalle .......................................................... 170

Elongation ................................................................ 28 Initiation ................................................................... 28 x Methionin ................................................................. 28 Termination ............................................................. 28

Translationshemmer

Xenologe Organe ........................................................ 165 Xenotransplantat ......................................................... 165 Xenotransplantation .................................................... 165

256 Stichwortverzeichnis

RechtIiche Aspekte ................................................ 166 Zellspreitung ................................................................. 86 Xylitol ......................................................................... 106 Zellwand ....................................................................... 11

Zenapax® .................................................................... 229

z Zentrifugation ............................................................... 93 Zetafilter ........................................................ '" .......... 200

Zeitstop ....................................................................... 188 Zeta-Potenzial ............................................................. 106 ZelIkern ......................................................................... 11 ZeIIkultur

Zilienbewegung .......................................................... 118 Zink-Protamin ............................................................. -212

Biosyntheseleistung ................................................. 51 Zirlconpartikel ............................................................... 81 Vergleich ................................................................. 52

Zelllinien ....................................................................... 13 Zitronensllure ................................................. _ ........... _ .. 18 ZOladex® ..................................................................... 123

CI27-BPV .................................................... , .......... 22 ZOmacton® .................................................................. 224 CHO-DHFR ............................................................. 22 Zuckergradient ............................................................ 136 CHO-GS .................................................................. 22 Zulassungsunterlagen .................................................. 188 CHO-NEOSPLA. ............................................ ......... 22 Zytokine ...................................................................... 216 HeLa ........................................................................ 22 Zytoplasma ................................................................... 11 NSO-GS ................................................................... 22